Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project.

Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: Major impact of cognition

“…This high prevalence of vulnerability confirms the findings from As for the G8 screening tool, we found that it identified vulnerability in clinically fit older patients with haematological malignancies with moderate diagnostic accuracy. This differs from other studies which demonstrated that the G8 had a good diagnostic accuracy for identifying patients who might benefit from additional investigations (23).…”

“…This discrepancy may be explained by the fact that these studies focused either exclusively on solid tumors, or on a mixed population with a minority of haematological malignancies, and that the G8 screening tool was initially validated in a large French oncogeriatric population (23). In this large oncologic population, the sensitivity (S) of the G8 was 76.6% and the specificity (Sp) was 64.4%.…”

“…In addition, we selected a population of clinically fit older patients admitted to receive chemotherapy. It is important to remember that, initially, the G8 screening tool was built only to predict the need for full CGA in older patients (23). The poor prognostic value of the CGA total score in our population can be explained by the fact that -in malignant haemopathies -other important prognostic factors related to the disease itself such as anemia (25), albumin level (26) or poor cytogenetics (27), which were not assessed in this study, have a more prominent influence on survival.…”

Ability of the Comprehensive Geriatric Assessment to Predict Frailty in Older People Diagnosed with Cancer in a General Hospital

“…[28][29][30][31][32] However, there are no studies that compare all of them side by side, nor are there studies that consider the G-8 questionnaire as a detection method for the risk of frailty, despite the fact that it was developed specifically for the cancer population and has proven to be a very promising survey in this area. 33 Thus far, most publications include the Vulnerable Elders Survey-13 (VES-13) questionnaire as the main detector of frailty risk, but future studies will have to show a more complete response to this question. We routinely apply the BQ to the elderly at the cancer unit in our hospital because we are investigating and clarifying its role in the field of oncogeriatrics.…”

The International Society of Geriatric Oncology Conference: Paris 2011

“…It included a large number of presentations on geriatric assessment instruments utilized in various clinical settings, from preoperative assessment and screening tools, such as the Gröningen frailty indicator [17] and the French G8 [18], to scores allowing for the prediction of treatment toxicity, such as the one developed by the Cancer and Aging Research Group [19] and the Chemotherapy Risk Assessment Scale for HighAge patients program from the University of South Florida, USA [20]. -Require large Phase III trials to oversample older cancer patients in order reach a meaningful percentage of their cohorts, and to structure their ana lysis to provide results specific and pertinent to this population -Extend Phase II and III trials to patients with high levels of comorbidity or functional impairment with stratified accruals or extension cohorts -Design specific trials for older cancer patients • Promote multidisciplinary, basic/translational research on the interface of aging and cancer…”